Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Ovarian Neoplasms 28Small Cell Lung Carcinoma 26Lung Neoplasms 20Neuroblastoma 17Carcinoma, Ovarian Epithelial 17Fallopian Tube Neoplasms 12Brain Neoplasms 10Uterine Cervical Neoplasms 8Sarcoma 8Leukemia 8Leukemia, Myeloid, Acute 6Central Nervous System Neoplasms 6Recurrence 5Medulloblastoma 5Lymphoma 5Gliosarcoma 5Glioblastoma 5Sarcoma, Ewing 4Rhabdoid Tumor 4Retinoblastoma 4Osteosarcoma 4Neuroectodermal Tumors, Primitive, Peripheral 4Neoplasms 4Burkitt Lymphoma 4Wilms Tumor 3Neoplasm Metastasis 3Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Glioma 3

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Fallopian Tube Mucinous Adenocarcinoma × Topotecan × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡